Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flonotinib for JAK inhibitor-refractory/relapsed/intolerant intermediate-2/high-risk myelofibrosis
CTR20255081Phase 2Active
- Sponsor
- Zeling Biopharma
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of flonotinib in myelofibrosis (MF), primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), post-essential thrombocythemia myelofibrosis (PET-MF), sponsored by Zeling Biopharma. Started Apr 2026; status: active.
02
Drugs
flonotinib
03
Conditions
myelofibrosis (MF)primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)post-essential thrombocythemia myelofibrosis (PET-MF)
Beyond the preview
Go deeper on CTR20255081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20255081.